Optimal timing of highly active anti-retroviral treatment (HAART) in HIV-infected patients with newly diagnosed TB
This trial is testing if HIV-infected TB patients with CD4 counts higher than 220 benefit from earlier initiation of antiretroviral (ARV) therapy. More than 1600 patients are being followed in South Africa, United Republic of Tanzania, Uganda, and Zambia. This study is the first among currently published optimal timing studies to evaluate safety and efficacy of concomitant use of antiretroviral and anti-TB therapies among HIV-infected TB patients with comparatively high CD4 counts. It’s anticipated that the result of this study will contribute to the emerging body of evidence for managing these categories of patients.
TB–HAART PK study
This is an embedded study within the ongoing main TB-HAART study being conducted in South Africa. It is investigating the potential impact of varying levels of immunodeficiency on absorption of both anti-TB and antiretroviral drugs.